Canada - English - Health Canada

vita health products inc - acetylsalicylic acid - tablet (delayed-release) - 81mg - acetylsalicylic acid 81mg - salicylates

Canada - English - Health Canada

vita health products inc - acetylsalicylic acid - tablet (delayed-release) - 81mg - acetylsalicylic acid 81mg - salicylates

Canada - English - Health Canada

apotex inc - acetylsalicylic acid - tablet (delayed-release) - 81mg - acetylsalicylic acid 81mg - salicylates

Canada - English - Health Canada

laboratoire riva inc. - acetylsalicylic acid - tablet (delayed-release) - 81mg - acetylsalicylic acid 81mg - salicylates

Canada - English - Health Canada

vita health products inc - acetylsalicylic acid - tablet (enteric-coated) - 81mg - acetylsalicylic acid 81mg - salicylates

Canada - English - Health Canada

laboratoires trianon inc. - acetylsalicylic acid - tablet (delayed-release) - 81mg - acetylsalicylic acid 81mg - salicylates

Canada - English - Health Canada

apotex inc - acetylsalicylic acid - tablet (delayed-release) - 81mg - acetylsalicylic acid 81mg - salicylates

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - amphotericin b -

New Zealand - English - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - amphotericin b 50mg - powder for injection - 50 mg - active: amphotericin b 50mg excipient: cholesterol hydrochloric acid alpha-tocopherol distearoylphosphatidylglycerol phosphatidylcholines, soya, hydrogenated phosphatidylglycerols as sodium salt sodium hydroxide sodium succinate sucrose - ambisome is indicated for: · prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for · the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b. ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Israel - English - Ministry of Health

rafa laboratories ltd - dipyridamole - tablets - dipyridamole 75 mg - dipyridamole - dipyridamole - as an adjunct to oral anticoagulants for prophylaxis of thromboembolism associated with prosthetic heart valves. reduction of proteinuria in the nephrotis syndrome. treatment of membranoproliferative glomerulonephritis. prevention of pre-eclampsia in the final trimester of pregnancy. prevention of transplant artery stenosis. prevention of post-operative thromboembolic complications of coronary artery surgery. in combination with acetylsalicylic acid in cases of recurrent deep vein thrombosis resistant to oral anticoagulants. prevention of thrombogenic manifestations. as an alternative to exercise stress in thallium myocardial imaging particularly in patients unable to exercise or in those for whom exercise may be contraindicated.